Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib placebo-controlled study of the MVA-MERS-S_DF-1 vaccine in healthy adults
NL-OMON50932Phase 1Active, not recruiting
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MVA-MERS-S in Middle East respiratory syndrome (MERS) (5 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoints: Overall safety and tolerability, Local reactogenicity and 2 more. Started Oct 2021; status: active, not recruiting.
02
Drugs
MVA-MERS-S
03
Conditions
Middle East respiratory syndrome (MERS)
Beyond the preview
Go deeper on NL-OMON50932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50932.